We revealed that FBXW7 effectively abated the expression and release of HMGB1, thereby suppressing TLR4 and RAGE signaling to attenuate inflammation and consequent insulin resistance, ultimately ameliorating NAFLD. The gene discussed is HMGB1; the disease is metabolic dysfunction-associated steatotic liver disease.